UX007
Phase 3Small molecule
UltragenyxUX007 is one of 15 small molecule programs targeting Movement Disorder. It is currently in Phase 3.
1
Indications
5
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Movement Disorder
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesApproved
Keppra
UCBApproved
Feosol
AAuerbach Hematology Oncology Associates P C
Approved
Pepcid
KKenvue Brands
Approved
Inderal
Mylan Pharmaceuticals IncPhase 2
BIIB122
BiogenPhase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 1
Zyprexa
MMODAG GmbH
Phase 1
Risperdal
WWim Janssens
Phase 1
UX007
UltragenyxPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)2 trials
Treatment1 trial
Safety and Efficacy1 trial
Movement Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UX007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company